CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
International Journal of Molecular Sciences · 29.08.2023 · 24 (17) · 13364
DOI: 10.3390/ijms241713364 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.08.2023. Verfasst von Vita Golubovskaya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Multiple Myeloma. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Promab Biotechnologies.
Abstract (Originalsprache)
Natural killer (NK) cells are cytotoxic lymphocytes that are critical for the innate immune system. Engineering NK cells with chimeric antigen receptors (CARs) allows CAR-NK cells to target tumor antigens more effectively. In this report, we present novel CAR mRNA-LNP (lipid nanoparticle) technology to effectively transfect NK cells expanded from primary PBMCs and to generate functional CAR-NK cells. CD19-CAR mRNA and BCMA-CAR mRNA were embedded into LNPs that resulted in 78% and 95% CAR expression in NK cells, respectively. BCMA-CAR-NK cells after transfection with CAR mRNA-LNPs killed multiple myeloma RPMI8226 and MM1S cells and secreted IFN-gamma and Granzyme B in a dose-dependent manner in vitro. In addition, CD19-CAR-NK cells generated with CAR mRNA-LNPs killed Daudi and Nalm-6 cells and secreted IFN-gamma and Granzyme B in a dose-dependent manner. Both BCMA-CAR-NK and CD19-CAR-NK cells showed significantly higher cytotoxicity, IFN-gamma, and Granzyme B secretion compared with normal NK cells. Moreover, CD19-CAR-NK cells significantly blocked Nalm-6 tumor growth in vivo. Thus, non-viral delivery of CAR mRNA-LNPs can be used to generate functional CAR-NK cells with high anti-tumor activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA.
- Laboratory for Critical Quality Attributes of Cell Therapy Products, Forevertek Biotechnology, Janshan Road, Changsha Hi-Tech Industrial Development Zone, Changsha 410205, China.
ORCID-Profile: Shiming Zhang
Förderung
- Promab Biotechnologies
Zitieren
APA
Golubovskaya, V., Sienkiewicz, J., Sun, J., Zhang, S., Huang, Y., Zhou, H., Harto, H., Xu, S., Berahovich, R., & Wu, L. (2023). CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. International Journal of Molecular Sciences, 24(17), 13364. https://doi.org/10.3390/ijms241713364
Vancouver
Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, et al. CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. International Journal of Molecular Sciences. 2023;24(17):13364. doi:10.3390/ijms241713364
BibTeX
@article{Golubovskaya2023,
author = {Golubovskaya, Vita and Sienkiewicz, John and Sun, Jinying and Zhang, Shiming and Huang, Yanwei and Zhou, Hua and Harto, Hizkia and Xu, Shirley and Berahovich, Robert and Wu, Lijun},
title = {CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {17},
pages = {13364},
doi = {10.3390/ijms241713364}
}
EUVIMED